Literature DB >> 22119689

What can ADHD without comorbidity teach us about comorbidity?

Toshinobu Takeda1, Paul J Ambrosini, Rachel deBerardinis, Josephine Elia.   

Abstract

Neuropsychiatric comorbidity in ADHD is frequent, impairing and poorly understood. In this report, characteristics of comorbid and comorbid-free ADHD subjects are investigated in an attempt to identify differences that could potentially advance our understanding of risk factors. In a clinically-referred ADHD cohort of 449 youths (ages 6-18), age, gender, IQ, SES and ADHD symptoms were compared among ADHD comorbid free subjects and ADHD with internalizing and externalizing disorders. Logistic regression analyses were also carried out to investigate the relationship between comorbidity and parental psychiatric status. Age range was younger in the ADHD without comorbidity and older in ADHD+internalizing disorders. No significant difference in IQ or SES was found among ADHD comorbid and comorbid-free groups. ADHD with internalizing disorder has a significantly greater association with paternal psychiatric conditions. After matching by age, gender, IQ and SES, ADHD with externalizing disorders had significantly higher total ADHD, hyperactivity/impulsivity score and single item score of difficulty awaiting turn than ADHD without comorbidity and ADHD with internalizing disorders. Older age ranges, ADHD symptom severity and parental psychopathology may be risk factors for comorbidity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22119689     DOI: 10.1016/j.ridd.2011.09.024

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  7 in total

1.  Is the prevalence of ADHD in Turkish elementary school children really high?

Authors:  Eyup Sabri Ercan; Öznur Bilaç; Taciser Uysal Özaslan; Luis Augusto Rohde
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-05-23       Impact factor: 4.328

2.  Attention-deficit/hyperactivity disorder without comorbidity is associated with distinct atypical patterns of cerebral microstructural development.

Authors:  Vitria Adisetiyo; Ali Tabesh; Adriana Di Martino; Maria F Falangola; Francisco X Castellanos; Jens H Jensen; Joseph A Helpern
Journal:  Hum Brain Mapp       Date:  2013-08-01       Impact factor: 5.038

3.  Reliability and validity of ADHD diagnostic criteria in the Assessment System for Individuals with ADHD (ASIA): a Japanese semi-structured diagnostic interview.

Authors:  Toshinobu Takeda; Yui Tsuji; Teruhisa Uwatoko; Hiroshi Kurita
Journal:  BMC Psychiatry       Date:  2015-06-20       Impact factor: 3.630

4.  Comorbidity of attention deficit hyperactivity disorder with personality disorders in homeless people.

Authors:  Carlos Salavera; José Luis Antoñanzas; Juan Carlos Bustamante; José Carrón; Pablo Usán; Pilar Teruel; Carmen Bericat; Lucía Monteagudo; Soledad Larrosa; José M Tricás; Orosia Lucha; Raquel Noé; Laurane Jarie; Raquel Cerra
Journal:  BMC Res Notes       Date:  2014-12-16

5.  Cognitive impairment in patients with Neuro-Sjögren.

Authors:  Tabea Seeliger; Lena Jacobsen; Merle Hendel; Lena Bönig; Nils K Kristian Prenzler; Thea Thiele; Diana Ernst; Torsten Witte; Martin Stangel; Bruno Kopp; Thomas Skripuletz
Journal:  Ann Clin Transl Neurol       Date:  2020-07-06       Impact factor: 4.511

6.  Comorbid externalising behaviour in AD/HD: evidence for a distinct pathological entity in adolescence.

Authors:  Sharnel Perera; David Crewther; Rodney Croft; Hannah Keage; Daniel Hermens; C Richard Clark
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

7.  FACT: a randomised controlled trial to assess the feasibility of QbTest in the assessment process of attention deficit hyperactivity disorder (ADHD) for young people in prison-a feasibility trial protocol.

Authors:  Charlotte Lennox; Charlotte Lucy Hall; Lesley-Anne Carter; Bryony Beresford; Susan Young; Abdullah Kraam; Nikki Brown; Lloyd Wilkinson-Cunningham; Mindy Reeves; Prathiba Chitsabesan
Journal:  BMJ Open       Date:  2020-01-20       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.